Study of Tamsulosin to Prevent Urinary Retention After Thoracic Cancer Surgery in Men Aged 55 and Older

What this Trial Is About

This research aims to evaluate whether the use of Tamsulosin can reduce the high rate of postoperative urinary retention POUR in older men undergoing thoracic cancer surgery. POUR is a common issue, especially in older men with enlarged prostates, leading to urinary tract infections, discomfort, and longer hospital stays. This pilot study focuses on men aged 55 and older scheduled for oncological thoracic surgery to see if Tamsulosin can help lower POUR incidence and identify when normal urinary function returns after surgery. Participants will receive a prescription for Tamsulosin at a dose of 0.4 mg daily, starting seven days before their planned surgery and continuing up to the day of surgery. They will take the medication with a meal and record their daily usage in a diary. After surgery, bladder function will be monitored using ultrasound to measure urine volume and residual urine. If spontaneous urination does not occur or excess urine remains, standard bladder management including intermittent catheterization may be applied based on specific guidelines. During the study, researchers will observe and record whether participants can urinate spontaneously within 6 to 8 hours after surgery, the timing and volume of urination within 24 hours, and the amount of residual urine. Those unable to urinate spontaneously may receive catheter interventions. The study will include regular assessments using a BladderScanner and follow participants until urinary function resumes. The total study duration varies depending on surgery and recovery timelines.

Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery